Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis-Reference-Cited by-同舟云学术

Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis

Published:2018-07-02 Issue: Volume: Page:
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:

Author:

Moe Sharon M¹²,Long Jin³,Schwantes-An Tae-Hwi Linus⁴,Decker Brian S¹,Wetherill Leah⁴,Edenberg Howard J⁴⁵,Xuei Xiaoling⁴,Vatta Matteo⁴,Foroud Tatiana M⁴,Chertow Glenn M³

Affiliation:

1. Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

2. Department of Medicine, Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA

3. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

4. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA

5. Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

Funder

Amgen

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfy191/25115280/gfy191.pdf

Reference30 articles.

1. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis;Chertow;N Engl J Med,2012

2. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial;Chertow;Nephrol Dial Transplant,2012

3. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial;Wheeler;J Am Heart Assoc,2014

4. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD;Landray;Am J Kidney Dis,2006

5. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease;Baigent;Am J Kidney Dis,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOME GENETIC RISK MARKERS FOR POSTINFARCTION HEART FAILURE;"Medical & pharmaceutical journal "Pulse";2023-02-25

2. THE EFFECT OF NOS3 AND AGTR1 GENOTYPES ON THE COURSE OF THE ARTERIAL HYPERTENSION FOR THE OVERWEIGHT OR OBESE PATIENTS;Wiadomości Lekarskie;2022

3. A systematic review of nonsynonymous single nucleotide polymorphisms in the renin–angiotensin–aldosterone system;Cardiology Journal;2021-05-28

4. The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis;Cardiorenal Medicine;2021

5. Joint testing of donor and recipient genetic matching scores and recipient genotype has robust power for finding genes associated with transplant outcomes;Genetic Epidemiology;2020-08-11